Literature DB >> 2447410

No evidence for a direct vasodilatory effect of celiprolol on human vasculature in vivo or in vitro.

A Hughes1, G Martin, P Goldberg, S Thom, P Sever.   

Abstract

Celiprolol is reported to be a new cardioselective beta blocker with novel ancillary properties including vasodilator effects. The purpose of this study was to investigate whether celiprolol possesses a direct vasodilatory effect on human vasculature in vivo and in vitro. We studied the in vivo effects of intra-arterial celiprolol (1-100 micrograms/min i.a.) on forearm blood flow (FBF). Forearm blood was measured by venous occlusion plethysmography. Possible vasorelaxant actions of celiprolol on human vascular smooth muscle were studied using segments of isolated human saphenous vein in vitro. The effect of celiprolol was investigated on resting tone or noradrenaline induced tone. Possible alpha 2-adrenoceptor antagonist effects of celiprolol were assessed using celiprolol as an antagonist of BHT933 induced constriction. Celiprolol was without significant effect on FBF and failed to relax isolated saphenous vein segments preconstricted with noradrenaline. The weak alpha 2-adrenoceptor antagonist action of celiprolol was demonstrable in human saphenous vein. This study does not provide evidence for a direct vasodilatory effect of celiprolol on human vasculature.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2447410     DOI: 10.1097/00005344-198711000-00015

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  5 in total

1.  The structure of celiprolol.

Authors:  N Kumar; C Strohbeck; H L Ammon
Journal:  Pharm Res       Date:  1992-03       Impact factor: 4.200

Review 2.  Do partial agonist beta-blockers have improved clinical utility?

Authors:  J D Fitzgerald
Journal:  Cardiovasc Drugs Ther       Date:  1993-06       Impact factor: 3.727

Review 3.  Celiprolol. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in cardiovascular disease.

Authors:  R J Milne; M M Buckley
Journal:  Drugs       Date:  1991-06       Impact factor: 9.546

4.  Effect of pretreatment with the selective beta 1-adrenoceptor antagonist bisoprolol on the subsequent cardiovascular actions and beta-adrenoceptor subtype specific occupancy of celiprolol in healthy man.

Authors:  C de Mey; K Beithaupt; D Palm; U Fuhr; G G Belz
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 5.  Adverse reactions with beta-adrenoceptor blocking drugs. An update.

Authors:  R V Lewis; C Lofthouse
Journal:  Drug Saf       Date:  1993-10       Impact factor: 5.606

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.